Group 1 - Medtronic has a historically high dividend yield of around 3% and is working on improving its business performance, which could make it a strong healthcare stock to consider [1] - The company has faced challenges due to a development dry spell but is now gaining traction with new surgical robots and cardiac ablation systems [2] - Medtronic is focusing on its most profitable businesses, with a significant move being the spinoff of its diabetes treatment division, which is expected to be immediately accretive to earnings [3] Group 2 - As new products are introduced, Medtronic's earnings growth may exceed Wall Street's expectations, driven by higher profit margins and increased revenues from R&D developments [4] - The current high yield provides an opportunity for investors to benefit while waiting for the market to recognize the improving fundamentals of Medtronic's business [4] - Medtronic's growth has stalled in recent years, but the company is actively bringing new products to market and focusing on its most profitable segments [6]